We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
OLUMIANT (Eli Lilly Australia Pty Ltd)
Product name
OLUMIANT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
232 (255 working days)
Active ingredients
baricitinib
Registration type
EOI
Indication
Alopecia Areata
OLUMIANT is indicated for the treatment of severe alopecia areata (AA) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 Pharmacodynamic properties; Clinical trials).